Short Interest Update on Alkermes plc (ALKS)

Alkermes plc (ALKS) : Traders are negative on Alkermes plc (ALKS), as it has 2.9% of short positions outstanding compared to its float. The total shorts have reduced by -63,404 shares, which is a -1.4% reduction. From Jul 29, 2016, to August 15, 2016, the shorts came down from,4,448,018 to 4,384,614 shares. While the daily trading volume of the stock is 610,481, there are 7 days remaining to cover the open short positions. The short interest indicates that the traders dont see a large downside in the stock from the current levels. The short interest information was released on Wednesday Aug 24th after the market close.

Alkermes plc (NASDAQ:ALKS): The stock opened at $46.48 on Wednesday but the bulls could not build on the opening and the stock topped out at $47.60 for the day. The stock traded down to $44.41 during the day, due to lack of any buying support eventually closed down at $44.45 with a loss of -4.41% for the day. The stock had closed at $46.50 on the previous day. The total traded volume was 1,065,152 shares.


In a related news, The Securities and Exchange Commission has divulged that Mitchell Paul J, director of Alkermes Plc., had unloaded 2,000 shares at an average price of $49.48 in a transaction dated on August 4, 2016. The total value of the transaction was worth $98,960.

Alkermes Public Limited Company is a biopharmaceutical company. The Company is engaged in researching, developing and commercializing, both with partners and on its own, pharmaceutical products that are designed to meet unmet medical needs of patients in major therapeutic areas. The Company has a portfolio of more than 20 products and a clinical pipeline of product candidates being developed for the treatment of central nervous system (CNS) disorders, such as addiction, schizophrenia and depression. The Company is conducting clinical studies on new pharmaceutical products. These include Aripiprazole Lauroxil, ALKS 5461, ALKS 3831, ALKS 8700 and RDB 1419. The Companys main marketed products include RISPERDAL CONSTA, INVEGA SUSTENNA/XEPLION, AMPYRA/FAMPYRA, BYDUREON and VIVITROL.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.